Seattle-based biotech company Proniras Corp. has raised $4.6M, according to a filing with the Securities and Exchange Commission. The filing notes the money is in the form of equity funding and other securities. It also shows that Proniras is looking to raise an additional $7.6M.
Proniras, founded in 2017, is developing a treatment called tezampanel to help with opioid withdrawal symptoms. The company says its lead candidate could also help with other conditions, including epilepsy, neonatal abstinence syndrome, and toxic exposure to organophosphate pesticides, among others.